Ioflupane (123i) Rotop

Ioflupane, the active ingredient in Ioflupane (123i) Rotop, is a diagnostic radiopharmaceutical presented as an injectable solution for intravenous use. It enables visualization of presynaptic dopamine transporters to aid diagnosis of Parkinsonian syndromes and related movement disorders in the central nervous system.\n\nGNH India supplies Ioflupane (123i) Rotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Ioflupane (123i) Rotop is used to assess dopaminergic neuronal integrity in disorders affecting the central nervous system.\n\nParkinsonian syndrome: provides quantitative imaging of dopamine transporter loss to support diagnosis.\nEssential tremor vs. Parkinson's disease: helps differentiate tremor etiologies by visualizing presynaptic dopamine activity.\nNeurodegenerative disorder assessment: evaluates the extent of dopaminergic neuron loss in conditions such as multiple system atrophy or progressive supranuclear palsy.

Adverse reactions may occur following administration of Ioflupane (123i) Rotop.\n\nCommon Side Effects:\n- Headache: mild to moderate intensity.\n- Nausea or vomiting: transient gastrointestinal discomfort.\n- Dizziness or light‑headedness: often resolves spontaneously.\n- Injection site pain or erythema: mild local irritation.\n- Transient hypotension: temporary blood pressure drop.\n- Dry mouth: temporary reduction in salivation.\n\nSerious or Rare Side Effects:\n- Allergic reaction: rash, pruritus, or urticaria.\n- Anaphylaxis: severe, potentially life‑threatening hypersensitivity.\n- Severe hypotension: marked blood pressure decrease requiring intervention.\n- Radiation‑induced skin injury: localized erythema at injection site.\n- Seizures: rare neurologic events.\n- Persistent nausea/vomiting: may require anti‑emetic therapy.

Prior to using Ioflupane (123i) Rotop, consider the following safety measures.\n\nPregnancy: unknown safety; avoid unless essential for maternal care.\nBreastfeeding: unknown; weigh potential risks to infant before administration.\nRenal impairment: assess renal function as excretion is primarily renal.\nConcomitant dopamine‑blocking agents: may interfere with imaging results.\nRadiation safety: follow local regulations for handling and disposal of radioactive material.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ioflupane (123i) Rotop may interact with other substances that affect dopamine transporter binding or radiation exposure.\n\nMajor Interactions (Avoid):\n- Cocaine or amphetamines: block DAT and markedly reduce tracer uptake.\n- Monoamine oxidase inhibitors (MAOIs): may alter dopamine metabolism and affect imaging.\n- Other radiopharmaceuticals: cumulative radiation dose may exceed safety limits.\n\nModerate Interactions (Monitor Closely):\n- Antidepressants (SSRIs, SNRIs): can modestly affect DAT binding.\n- Antihypertensive agents: may influence cerebral blood flow and tracer distribution.\n- Diuretics: potential alteration of renal clearance of the radiotracer.